Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicentric, Open-label Clinical Investigation to Evaluate the Performance and Safety of the Use of IRIDIUM GARZE as Adjuvant Treatment in Patients With Blepharitis or Blepharoconjunctivitis

NCT07431385 is registered in ClinicalTrials.gov with Fidia Farmaceutici s.p.a. as lead sponsor.

NCT NCT07431385
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07431385 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicentric, Open-label Clinical Investigation to Evaluate the Performance and Safety of the Use of IRIDIUM GARZE as Adjuvant Treatment in Patients With Blepharitis or Blepharoconjunctivitis
Lead sponsor
Fidia Farmaceutici s.p.a.
Phase
Not applicable
Overall status
Completed
Start date
September 17, 2025
Completion date
April 14, 2026
Enrollment
80 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

blepharitis, blepharoconjunctivitis